Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × Sorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 196 Carcinoma, Renal Cell 69 Liver Neoplasms 59 Neoplasms 44 Leukemia, Myeloid, Acute 34 Neoplasm Metastasis 30 Carcinoma, Non-Small-Cell Lung 27 Breast Neoplasms 27 Melanoma 22 Kidney Neoplasms 19 Pancreatic Neoplasms 15 Sarcoma 14 Prostatic Neoplasms 13 Lung Neoplasms 13 Brain Neoplasms 12 Recurrence 11 Thyroid Neoplasms 10 Glioblastoma 10 Colorectal Neoplasms 10 Carcinoma 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Myelodysplastic Syndromes 8 Multiple Myeloma 8 Urinary Bladder Neoplasms 6 Unspecified Adult Solid Tumor, Protocol Specific 6 Stomach Neoplasms 6 Rectal Neoplasms 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Ovarian Neoplasms 5 Liver Diseases 5

Interventions

nimotuzumab 1 atezolizumab 1 Tirapazamine 1 Stents 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01470495 2017-03-28

REPEAT

Southwest Hospital, China

Phase NA Unknown

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡